爱美客：控股子公司REGEN公司涉及重大仲裁

Core Viewpoint - Aimei Ke (300896) announced that its subsidiary REGEN Biotech, Inc. has initiated arbitration against Da Tu Medical Devices (Shanghai) Co., Ltd. regarding a distribution contract dispute, with a preliminary claim of RMB 1.6 billion [1] Group 1 - REGEN Biotech, Inc. filed for arbitration with the Shenzhen International Arbitration Court on August 13 [1] - The arbitration request pertains to a dispute over the validity of an exclusive agency agreement for AestheFill products [1] - The Shenzhen International Arbitration Court accepted the case on August 7 [1] Group 2 - The applicant seeks a ruling to confirm the validity of the exclusive agency rights agreement [1] - The specific compensation amount has not been clearly defined, but a preliminary claim of RMB 1.6 billion has been made [1]